Template-directed dye-terminator incorporation with fluorescence polarization detection for analysis of single nucleotide polymorphism implicated in sepsis

Journal of Molecular Diagnostics

Volumn 4, Issue 4, 2002, Pages 209-215

  Freeman, Bradley D ^a   Buchman, Timothy G ^a   McGarth, Sean ^a   Tabrizi, Arash Rafii ^a   Zehnbauer, Barbara A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DNA TEMPLATE; FLUORESCENCE POLARIZATION; GENE ASSIGNMENT; GENE IDENTIFICATION; GENE SEQUENCE; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MUTATIONAL ANALYSIS; PROCESS OPTIMIZATION; SAMPLE SIZE; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0036862118     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-1578(10)60705-2     Document Type: Article

References (31)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310
2. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994, 120:771-783
3. Freeman BD, Eichacker PQ, Natanson C. The role of inflammation in sepsis and septic shock: a meta-analysis of both clinical and pre-clinical trials of anti-inflammatory therapies. Inflammation: Basic Principles and Clinical Correlates, ed 3. Edited by Gallin J, Snyderman R. Philadelphia, Lippincott Williams & Wilkins, 1999, pp 965-976
4. Freeman B, Natanson C: Anti-inflammatory therapies in sepsis and septic shock. Expert Opinion on Investigational Drugs 2000, 9:1651-1663
5. Freeman BD, Parrillo JE, Natanson C. Septic shock and multiple organ failure. Critical Care Medicine, ed 2. Edited by Parrillo JE, Dellinger P. St. Louis, MO, Mosby Publishing Co, 2001
6. Kay CA: Can better measures of cytokine responses be obtained to guide cytokine inhibition. Cambridge Health Institutes' Designing Better Drugs and Clinical Trials for Sepsis/SIRS: Reducing Mortality to Patients and Suppliers, Washington, DC, 1996
7. Freeman BD, Buchman TG: Coagulation inhibitors in the treatment of sepsis. Expert Opinion on Investigational Drugs 2002, 11:69-74
8. Zeni F, Freeman BD, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997, 25: 1095-1100
9. Sorensen TIA, Nielsen GG, Anderson PK, Teasdale TW: Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988, 318:727-732
10. Tabrizi RT, Zehnbauer BA, Buchman TG, Freeman BD: Genetic markers in sepsis. J Am Coll Surg 2001, 192:106-117
11. Freeman BD, Zehnbauer B: Genetic susceptibility to infection and sepsis. Perspectives on Critical Care Infectious Disease. Edited by Eichacker PQ, Pugin J. Boston, Kluwer Academic Publishers, 2001, pp 69-80
12. Stuber F, Peterson M, Bokelmann F, Schade U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor concentrations and outcome of patients with severe sepsis. Crit Care Med 1996, 24:381-384
13. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JP: Association of TNF2, a TNF promotor polymorphism, with septic shock susceptibility and mortality: a multicenter study. J Am Med Assoc 1999, 282:561-568
14. Kumar A, Short J, Parrillo JE: Genetic factors in septic shock. J Am Med Assoc 1999, 282:579-581
15. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, Convit J, Blackwell JM: Polymoprhism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995, 182:1259-1264
16. Fishman D, Faulds G, Jeffrey R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376
17. Hermans PWM, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M: 4G/5G promotor polymorphism in the plasminogen-activator inhibitor-1 gene and outcome of meningococcal disease, Lancet 1999, 354:556-600
18. Majetschak M, Flohe S, Obertacke U, Schroder J, Staubach K, Nast-Kolb D, Schade FU, Stuber F: Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 1999, 230:207-214
19. Pociot F, Briant L, Jongeneel CV: Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993, 23:224-231
20. Westendorp RGJ, Hottenga JJ, Slagboom PE: Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999, 354:561-563
21. Chen X, Levine L, Kwok P-Y: Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res 1999, 9:492-498
22. Hsu TM, Chen X, Duan S, Miller RM, Kwok PY: Universal SNP genotyping assay with fluorescence polarization detection. BioTechniques 2001, 31:560-570
23. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874
24. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with selosis syndrome. J Am Med Assoc 1995, 273:934-941
25. Morse RH, Olomolaiue OO, Wood NAP, Keen LJ, Bidwell JL: Induced heteroduplex genotyping of TNF-α, IL-1b, IL-6, and IL-10 polymorphisms associated with transcriptional regulation. Cytokine 1999, 11:789-795
26. Tang G, Huang S, Yien H, Chen C, Wu C, Chi C, Wu C, Lui W, Chiu J, Lee T: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000, 28:2733-2736
27. Zheng C, Huang DR, Bergenbrant S, Sunblad A, Osterborg A, Bjorkholm M, Holm G, Yi Q: Interleukin 6, tumor necrosis factor α, interleukin 1 β, and interleukin 1 receptor antagonist promotor or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000, 109:39-45
28. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JK, Jones M, Frees K, Watt JL, Schwartz DA: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191
29. Department of Psychiatry Genotyping Shared Facility: SNP Genotyping. 2002, http://psy-svr1.bsd.uchicago.edu/geno/snp/snp.html
30. Hsu TM, Law SM, Duan S, Neri BP, Kwok PY: Genotyping single-nucleotide polymorphisms by the Invader assay with dual-color fluorescence polarization detection. Clin Chem 2001, 47:1373-1377
31. Kwok P-Y: High-throughput genotyping assay approaches. Pharmacogenomics 2000, 1:95-100